Skip to main content
. 2020 Oct 27;10:18400. doi: 10.1038/s41598-020-75376-z

Figure 3.

Figure 3

Terminal Complement complex, C5b-9, deposition and co-localization with PTX3 in first PBx of patients subsequently developing prostate cancer (group A) or not (group B). PTX3 protein expression (green; A and E) and C5b-9 deposition (red; B and F) were evaluated in the first PBx by double label immunofluorescence and confocal microscopy as detailed in Materials and Methods. TO-PRO-3 was used to stain nuclei (blue; C and G). Merged images (D and H) do not demonstrate any co-localization of the two protein signals. Mean fluorescence intensity (MFI) quantification confirmed the absence of C5b-9 deposition in both groups (I). Bar length = 50 µ.